

Date: March 11, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) - Acquisition of 8454 Equity Shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals - Subsidiary of the Company

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, we would like to inform that as per the approval accorded by the Management Committee of Board of Directors of the Senores Pharmaceuticals Limited (“the Company or “the Purchaser”), in their meeting held today i.e. March 11, 2025, the Company has entered into the Share Purchase Agreement (“SPA”) with certain shareholders (Public Category) of Havix Group Inc. D/B/A Aavis Pharmaceuticals (“Havix” or “the Target Company”) for acquisition of 8454 (Eight Thousand Four Hundred Fifty Four) equity shares of Havix aggregating to 3.73% of the total paid up share capital of Havix and subject to the terms and conditions as mentioned in the SPA.

Further, post the aforesaid acquisition, the shareholding of the Company in Havix will increase from 51.23% to 54.96%.

We have enclosed herewith the details required under Regulation 30 read with Para A (1) of Part A of Schedule III of the Listing Regulations and the SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 as **Annexure -1**.

We request you to take the above information on record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Encl.: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263

Annexure - 1
Disclosure under Regulation 30(6) read with Para A(1) of Part A of Schedule III of the Listing Regulations and the SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Havix Group Inc. D/B/A Aavis Pharmaceuticals ("Havix") is currently engaged in the business of developing, manufacturing and supplying of various finished formulations. The turnover of Havix for the financial year ended March 31, 2024 was USD 14,440,414.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The shares of Havix are being acquired from the shareholders of the Havix (Public Category) and hence it does not fall under the ambit of related party transaction. The transaction is being done at arm's length basis.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Senores Pharmaceuticals Limited, at present holds 51.23% of equity shares of Havix and the aforesaid acquisition of 8454 equity shares is being done to consolidate the direct holding of the Company in Havix - a subsidiary of the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Requisite approvals under Foreign Exchange Management Act, 1999 have been applied for.
6.	Indicative time period for completion of the acquisition	Within period 10 days from the date of execution of SPA.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	USD 160 per equity share.
9.	Percentage of shareholding/ control acquired and/or number of shares acquired	8454 (Eight Thousand Four Hundred Fifty-Four) equity shares constituting 3.73%, of the total paid up share capital of the Target Company.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Havix was incorporated under the laws of the State of Delaware on February 17, 2015. Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations.

Senores Pharmaceuticals Limited

 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: info@senorespharma.com

 W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263

Sr. No.	Particulars	Description						
		<p>The turnover of Havix for last 3 years is given below:</p> <p style="text-align: right;">(Amount in USD)</p> <table border="1" data-bbox="857 331 1412 441"> <thead> <tr> <th data-bbox="857 331 1036 384">Mar-22</th> <th data-bbox="1036 331 1224 384">Mar-23</th> <th data-bbox="1224 331 1412 384">Mar-24</th> </tr> </thead> <tbody> <tr> <td data-bbox="857 384 1036 441">7,336,642</td> <td data-bbox="1036 384 1224 441">8,814,761</td> <td data-bbox="1224 384 1412 441">14,440,414</td> </tr> </tbody> </table> <p>Country of presence: United States of America</p>	Mar-22	Mar-23	Mar-24	7,336,642	8,814,761	14,440,414
Mar-22	Mar-23	Mar-24						
7,336,642	8,814,761	14,440,414						

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263